Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Rises By 62.7%

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 283,200 shares, a growth of 62.7% from the February 28th total of 174,100 shares. Approximately 2.2% of the shares of the company are sold short. Based on an average daily volume of 8,500,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Several analysts have recently commented on the company. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Institutional Trading of Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC grew its stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,946 shares of the company’s stock after buying an additional 13,038 shares during the period. Geode Capital Management LLC owned 1.39% of Hoth Therapeutics worth $72,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Stock Down 1.9 %

Shares of HOTH traded down $0.02 on Monday, reaching $1.01. The stock had a trading volume of 151,201 shares, compared to its average volume of 3,413,166. The firm has a 50-day moving average of $1.13 and a 200 day moving average of $1.01. The firm has a market capitalization of $6.97 million, a PE ratio of -0.77 and a beta of 0.84. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. On average, sell-side analysts anticipate that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.